11/21
08:27 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
11/20
02:02 pm
biib
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
Low
Report
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
11/19
01:13 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
11/19
01:00 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
11/18
07:21 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
11/18
07:12 am
biib
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
Low
Report
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
11/18
04:37 am
biib
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
Low
Report
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
11/15
10:59 am
biib
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
Low
Report
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
11/15
08:04 am
biib
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/15
08:03 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an "outperform" rating on the stock.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an "outperform" rating on the stock.
11/15
05:59 am
biib
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/14
02:29 pm
biib
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance Canada]
Low
Report
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance Canada]
11/14
02:23 pm
biib
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance]
Low
Report
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance]
11/14
01:29 pm
biib
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Low
Report
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/14
11:26 am
biib
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease [Yahoo! Finance]
Low
Report
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease [Yahoo! Finance]
11/14
11:23 am
biib
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Low
Report
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
11/14
07:35 am
biib
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $190.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $190.00 price target on the stock.
11/6
01:26 pm
biib
BIIB vs. MYGN: Which Stock Is the Better Value Option? [Yahoo! Finance]
Low
Report
BIIB vs. MYGN: Which Stock Is the Better Value Option? [Yahoo! Finance]
11/5
11:04 am
biib
Are Investors Undervaluing Biogen (BIIB) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Biogen (BIIB) Right Now? [Yahoo! Finance]
11/4
11:43 am
biib
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/4
10:31 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at JPMorgan Chase & Co. from $220.00 to $210.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at JPMorgan Chase & Co. from $220.00 to $210.00. They now have a "neutral" rating on the stock.
10/31
08:03 pm
biib
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Low
Report
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
10/31
02:35 pm
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $190.00 to $180.00. They now have an "equal weight" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $190.00 to $180.00. They now have an "equal weight" rating on the stock.
10/31
02:35 pm
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $270.00 to $255.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $270.00 to $255.00. They now have an "outperform" rating on the stock.
10/31
01:35 pm
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at TD Cowen from $300.00 to $275.00. They now have a "buy" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at TD Cowen from $300.00 to $275.00. They now have a "buy" rating on the stock.